



Access continuous EtCO₂ monitoring and infusion therapy on a single platform

Alaris™ EtCO₂ Module



Continuous respiratory monitoring across all patient care areas

Alaris™ PCA Pause Protocol pauses patient-controlled analgesia (PCA) infusions when hospital-established respiratory rate alarm limits are exceeded.

This unique BD Alaris™ system feature helps you identify adverse events and manage respiratory complications. It enables continuous respiratory monitoring to reduce the risk of respiratory depression from opioid infusions.¹

Real-time EtCO₂ and PCA dose trend data

Display trending helps you view real-time patient PCA infusion dosing, respiratory rate, end-tidal carbon dioxide (EtCO₂) value and no breath event status. These capabilities help you assess and respond to the patient's physiological response to PCA therapy.



Alaris™ EtCO₂ Module provides high-performance:

- Easy-to-use plug and play technology
- A full array of FilterLine™ nonintubated ETCO₂ Patient Sampling Lines are available, featuring oral and nasal sampling as well as an innovative supplemental oxygen delivery system.
- For long-term monitoring, FilterLine™ sampling lines with drier moisture reduction technology are available
- Customizable profiles that add alarm limit flexibility across all patient care areas

Alaris™ EtCO₂ Module, with Medtronic Microstream™ Capnography technology

Alaris™ EtCO₂ Module promotes accuracy with:

- Small sampling size (50 mL/min) that measures accurate EtCO₂, respiratory rate, fractional inspired carbon dioxide (FiCO₂) and no breath values for all patient populations, from adult to neonatal
- Includes Smart Alarm for Respiratory Analysis™ Algorithm (SARA), which is engineered to reduce clinically insignificant respiratory rate alarms

Alaris™ EtCO₂ Module supports patient safety through:

- Adherence to current American Society of Anesthesiologists (ASA) and The Joint Commission standards recommending CO₂ monitoring for all anesthetized patients (*intubated and nonintubated*)²
- Added safety at the bedside to continuously monitor patient respiratory response to infusion therapy. When used with the Alaris™ PCA Module, it is the first and only infusion system to introduce PCA Pause Protocol, real-time EtCO₂ and PCA dose trend data
- Customizable alarm limits by care area utilizing Guardrails™ Software
- Visual indication of respiratory depression through capnography waveform

Medtronic provides these disposables:

- Intubated EtCO₂ and nonintubated EtCO₂ (*with or without O₂ administration*) FilterLine™ EtCO₂ Sampling Lines

Several societies have published guidelines promoting the utility of capnography for the detection or prevention of respiratory compromise in patients receiving opioids.

- Anesthesia Patient Safety Foundation (ASPF)³
- American Society of Anesthesiologists (ASA)⁴
- Institute for Safe Medication Practices Reducing Patient Harm from Opiates⁵
- Institute for Healthcare Improvement (IHI)⁶
- Joint Commission⁷

Specifications

Sampling rate	50 mL/min, nominal
EtCO ₂ measurement	0–99 mmHg (<i>at sea level</i>)
Respiration rate	0–150 breaths/min
FiCO ₂	0–99 mmHg (<i>at sea level</i>)
No breath limit	0–60 sec (<i>default = 30 sec</i>)

For more information, contact your BD sales consultant at 800.482.4822 or visit bd.com

References

1 Holmes A, Nichols C, Helmboldt G, et al. Bariatric surgery patients can be safely managed postoperatively on a medical-surgical unit utilizing continuous cardiorespiratory monitoring. *Surg Obes Relat Dis*. 2010;6(3):85-90. doi: 10.1016/j.soard.2010.03.093. 2 American Society of Anesthesiologists (ASA). *Basic Standards for Intraoperative Monitoring*, 1999. The Joint Commission, 2007. 3 Essential Monitoring Strategies to Detect Clinically Significant Drug-Induced Respiratory Depression in the Postoperative Period. Conclusions and Recommendations. APSF. <https://www.apsf.org/article/no-patient-shall-be-harmed-by-opioid-induced-respiratory-depression/>. Accessed September 28, 2011. 4 Horlocker TT, Burton AW, Connis RT, et al. Practice guidelines for the prevention, detection, and management of respiratory depression associated with neuraxial opioid administration. *Anesthesiology*. 2009;110(2):218-230. 5 HIGH ALERT Medication Feature: Reducing patient harm from opiates. <https://www.ismp.org/resources/high-alert-medication-feature-reducing-patient-harm-opiates>. Published February 22, 2007. Accessed February 14, 2019. 6 How-to Guide: Prevent Harm from High-Alert Medications. Institute for Healthcare Improvement. <http://www.ihc.org/resources/Pages/Tools/HowtoGuidePreventHarmfromHighAlertMedications.aspx>. Published 2012. Accessed February 14, 2019. 7 Safe use of opioids in hospitals. The Joint Commission. https://www.jointcommission.org/assets/1/18/SEA_49_opioids_8_2_12_final.pdf. Published August 8, 2012. Accessed February 14, 2019.

BD, San Diego, CA, 92130, U.S.

bd.com

Microstream, Smart Alarm for Respiratory Analysis and FilterLine are trademarks of Medtronic. BD, the BD Logo and Alaris are trademarks of Becton, Dickinson and Company or its affiliates. © 2019 BD. All rights reserved. 1910001618 (0819/QTY) BD-8778

